Literature DB >> 23752505

The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Jie Xue1, Bart Hoorelbeke, Ioannis Kagiampakis, Borries Demeler, Jan Balzarini, Patricia J Liwang.   

Abstract

Griffithsin (Grft) is a protein lectin derived from red algae that tightly binds the HIV envelope protein gp120 and effectively inhibits virus infection. This inhibition is due to the binding by Grft of high-mannose saccharides on the surface of gp120. Grft has been shown to be a tight dimer, but the role of the dimer in Grft's anti-HIV function has not been fully explored. To investigate the role of the Grft dimer in anti-HIV function, an obligate dimer of Grft was designed by expressing the protein with a peptide linker between the two subunits. This "Grft-linker-Grft" is a folded protein dimer, apparently nearly identical in structural properties to the wild-type protein. A "one-armed" obligate dimer was also designed (Grft-linker-Grft OneArm), with each of the three carbohydrate binding sites of one subunit mutated while the other subunit remained intact. While both constructed dimers retained the ability to bind gp120 and the viral surface, Grft-linker-Grft OneArm was 84- to 1,010-fold less able to inhibit HIV than wild-type Grft, while Grft-linker-Grft had near-wild-type antiviral potency. Furthermore, while the wild-type protein demonstrated the ability to alter the structure of gp120 by exposing the CD4 binding site, Grft-linker-Grft OneArm largely lost this ability. In experiments to investigate gp120 shedding, it was found that Grft has different effects on gp120 shedding for strains from subtype B and subtype C, and this might correlate with Grft function. Evidence is provided that the dimer form of Grft is critical to the function of this protein in HIV inhibition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23752505      PMCID: PMC3719714          DOI: 10.1128/AAC.00332-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  89 in total

1.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization.

Authors:  Elena Matei; Andrew Zheng; William Furey; Jeremy Rose; Christopher Aiken; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

3.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

4.  Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.

Authors:  Danielle Fontenot; Jason K Jones; Mohammad M Hossain; Pramod N Nehete; Eric M Vela; Victor A Dwyer; K Jagannadha Sastry
Journal:  Virology       Date:  2007-02-23       Impact factor: 3.616

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  A two-dimensional spectrum analysis for sedimentation velocity experiments of mixtures with heterogeneity in molecular weight and shape.

Authors:  Emre Brookes; Weiming Cao; Borries Demeler
Journal:  Eur Biophys J       Date:  2009-02-27       Impact factor: 1.733

10.  Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.

Authors:  Natasza E Ziółkowska; Shilpa R Shenoy; Barry R O'Keefe; James B McMahon; Kenneth E Palmer; Raymond A Dwek; Mark R Wormald; Alexander Wlodawer
Journal:  Proteins       Date:  2007-05-15
View more
  24 in total

1.  Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126.

Authors:  Kathryn Fischer; Kimberly Nguyen; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.

Authors:  Tiffany N Grooms; Hung R Vuong; Kevin M Tyo; Danial A Malik; Lee B Sims; Carli P Whittington; Kenneth E Palmer; Nobuyuki Matoba; Jill M Steinbach-Rankins
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections.

Authors:  Hung R Vuong; Kevin M Tyo; Jill M Steinbach-Rankins
Journal:  J Vis Exp       Date:  2017-10-31       Impact factor: 1.355

4.  Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral Hemagglutinin.

Authors:  Yuichiro Sato; Kinjiro Morimoto; Takanori Kubo; Takemasa Sakaguchi; Akira Nishizono; Makoto Hirayama; Kanji Hori
Journal:  Mar Drugs       Date:  2015-05-29       Impact factor: 5.118

5.  Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.

Authors:  Tinoush Moulaei; Kabamba B Alexandre; Shilpa R Shenoy; Joel R Meyerson; Lauren Rh Krumpe; Brian Constantine; Jennifer Wilson; Robert W Buckheit; James B McMahon; Sriram Subramaniam; Alexander Wlodawer; Barry R O'Keefe
Journal:  Retrovirology       Date:  2015-01-23       Impact factor: 4.602

Review 6.  Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential.

Authors:  Sabrina Lusvarghi; Carole A Bewley
Journal:  Viruses       Date:  2016-10-24       Impact factor: 5.048

Review 7.  Bulk production of the antiviral lectin griffithsin.

Authors:  Joshua L Fuqua; Krystal Hamorsky; Guruatma Khalsa; Nobuyuki Matoba; Kenneth E Palmer
Journal:  Plant Biotechnol J       Date:  2015-07-14       Impact factor: 9.803

Review 8.  HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview.

Authors:  Geoffrey Férir; Stephanie C Gordts; Dominique Schols
Journal:  Molecules       Date:  2014-12-15       Impact factor: 4.411

9.  Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV.

Authors:  Evangelia Vamvaka; Elsa Arcalis; Koreen Ramessar; Abbey Evans; Barry R O'Keefe; Robin J Shattock; Vicente Medina; Eva Stöger; Paul Christou; Teresa Capell
Journal:  Plant Biotechnol J       Date:  2016-01-23       Impact factor: 9.803

10.  Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.

Authors:  Keith Levendosky; Olga Mizenina; Elena Martinelli; Ninochka Jean-Pierre; Larisa Kizima; Aixa Rodriguez; Kyle Kleinbeck; Thierry Bonnaire; Melissa Robbiani; Thomas M Zydowsky; Barry R O'Keefe; José A Fernández-Romero
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.